Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Venetoclax Maintenance in AML
NCT05404906Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2022
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Relapse-free survival at 3 years. Started Jun 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05404906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404906.